Sign In
to Vote &
Create Storyboards.
 
AstraZeneca (NYSE:AZN) has announced plans to conduct two new clinical studies as part of PARTHENON, AstraZeneca's largest clinical trial program involving over 80,000 patients. The studies are designed to build scientific understanding of BRILINTA® (ticagrelor) tablets in additional high-risk patient populations. SOCRATES (Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES) is a global clinical trial involving 9,600 patients who have experienced ...
1
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard